Anita F. Das, PhD

Project Statistician
AD Stat Consulting
Guerneville, CA

Disclosure: Achaogen: Consultant
AntiobioTx: Consultant
Boston Pharmaceuticals: Consultant
Cempra: Consultant
ContraFect Corporation: Consultant
Iterum Therapeutics: Consultant
Nabriva: Consultant
Paratek: Consultant
Tetraphase: Consultant
UTILITY: Consultant
Wockhardt: Consultant

Presentation(s):

• LB3 - Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study

  Thursday, October 3
  2:05 PM – 2:15 PM